




RealRate

# PHARMACEUTICAL 2020

MANNKIND CORP

Rank 207 of 362



RealRate

• Financial Strength Rankings using Artificial Intelligence

• [www.realrate.ai](http://www.realrate.ai)



# PHARMACEUTICAL 2020

## MANNKIND CORP Rank 207 of 362

The relative strengths and weaknesses of MANNKIND CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of MANNKIND CORP compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 129% points. The greatest weakness of MANNKIND CORP is the variable Assets, Current, reducing the Economic Capital Ratio by 97% points.

The company's Economic Capital Ratio, given in the ranking table, is -222%, being 80% points above the market average of -303%.

| Input Variable                              | Value in 1000 USD |
|---|-------------------|
| Assets, Current                             | 60,757            |
| Cost of Goods Sold                          | 20,078            |
| Intangible Assets                           | 0                 |
| Liabilities, Current                        | 65,618            |
| Liabilities, Non-Current                    | 10,858            |
| Other Assets                                | 6,190             |
| Other Compr. Net Income                     | 0                 |
| Other Expenses                              | 5,988             |
| Other Liabilities                           | 207,775           |
| Other Net Income                            | -7,306            |
| Property and Equipment                      | 26,778            |
| Research and Development                    | 6,900             |
| Revenues                                    | 63,038            |
| Selling, General and Administrative Expense | 74,669            |

| Output Variable          | Value in 1000 USD |
|--------------------------|-------------------|
| Assets                   | 93,725            |
| Liabilities              | 284,251           |
| Expenses                 | 107,635           |
| Stockholders Equity      | -190,526          |
| Net Income               | -51,903           |
| Comprehensive Net Income | -51,903           |
| Economic Capital Ratio   | -222%             |

